
Lytix Biopharma Q1 2025 - Progress in NeoLIPA but Financial Weakness for Verrica

Redeye comments on Lytix Biopharma's first quarter review of 2025. The NeoLIPA study is progressing with a planned interim readout in Q3 2025. Despite the successful share issue in November 2024, Verrica currently does not have funding for the rest of 2025, which we discuss.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Lytix Biopharma Q1 2025 - Progress in NeoLIPA but Financial Weakness for Verrica](#)